$CRMD News

RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

CorMedix Therapeutics Announces U.S. Court Of Appeals Affirmed Patent Infringement Judgement Ruling Against Nexus Pharmaceuticals

CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run

CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms

CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat

Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)?

A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year Guidance

Cormedix Therapeutics to Participate in two Upcoming Investor Conferences

Cormedix Inc (CRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

CorMedix Inc. Q1 2026 Earnings Call Summary

CorMedix (CRMD) Q1 2026 Earnings Transcript

CorMedix Q1 Earnings Call Highlights

CorMedix Shares Jump After Revenue Beat and Higher Full-Year Guidance

CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised

CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript

CorMedix Inc (NASDAQ:CRMD) Surges After Blowout Q1 Earnings Beat and Raised Guidance

Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Cormedix Raises FY2026 Sales Guidance from $300.000M-$320.000M to $325.000M-$345.000M vs $308.224M Est

Cormedix Q1 2026 Earnings Call Transcript

Cormedix Q1 Adj. EPS $0.43 Beats $0.36 Estimate, Sales $127.427M Beat $105.017M Estimate